Michael Roberts, Adaptin Bio CEO
September 3, 2024 07:00 AM EDT
Startups
R&D

Ex­clu­sive: Duke spin­out launch­es in hopes of pre­vail­ing with brain can­cer bis­pe­cif­ic where Am­gen, Roche did not

Lei Lei Wu

News Reporter

Adaptin Bio is launch­ing with plans to bring a bis­pe­cif­ic T cell en­gager for glioblas­toma, a dead­ly form of brain can­cer, in­to the clin­ic. …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

CBER's deputy di­rec­tor de­parts as staff shake­up con­tin­ues

Blue­bird bio to sell to in­vest­ment funds af­ter strug­gling to make mon­ey from gene ther­a­pies

Eli Lil­ly stock­piles $548M of oral weight loss drug ahead of launch

FDA ap­proves first drug to treat ul­tra-rare lipid stor­age dis­ease

Will CRISPR mat­ter?

sponsored

Trust­ed pro­tec­tion: Why the cur­rent meningo­coc­cal vac­ci­na­tion sched­ule shouldn’t change with­out strong ev­i­dence

A service from the Financial Times